Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Recurrent Ovarian Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Delving Into the Patterns of Patient Engagement and Trends in Participation Within Recurrent Ovarian Cancer Clinical Trials
Overview
Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption. By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.
Primary outcome measures
- Number of patients who decide to participate in a recurrent ovarian cancer clinical trial [Time frame: 3 months]
- Rate of patients who remain in recurrent ovarian cancer clinical research to trial completion [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Aged ≥ 18 years old
- Able to comprehend the investigational nature of the protocol and provide informed consent
- Diagnosis of recurrent ovarian cancer
Exclusion criteria
- No diagnosis of recurrent ovarian cancer confirmed
- Inability to perform regular electronic reporting
- Patient does not understand, sign, and return consent form
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-crossover
Study locations
United States · 1 center
- Power Life Sciences — San Francisco
Publications
- Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104. PMID 30887020
- Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, Sulimanoff I. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015 Dec;13(6):1771-80. doi: 10.1017/S1478951515000127. Epub 2015 Mar 2. PMID 25728373
- Hilal Z, Schultheis B, Hartmann F, Dogan A, Cetin C, Krentel H, Schiermeier S, Tempfer CB. What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature. Anticancer Res. 2016 Oct;36(10):5365-5371. doi: 10.21873/anticanres.11110. PMID 27798900
Identifiers
NCT: NCT06070285 · 72827906